{"analyses":[{"ciLowerLimit":"5.426","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.699","groupDescription":"CIN1/4 in previous cycle as cycle-level predictor for CIN/FN-related chemotherapy disturbance","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"8.931","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"0.152","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.740","groupDescription":"Hematological cancer (vs. oncologic) as patient-level predictor for CIN/FN-related chemotherapy disturbance","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","paramType":"Odds Ratio (OR)","paramValue":"0.336","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"0.999","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.000","groupDescription":"Cancer patients seen in 2009 (per 1 patient) as center-level predictor for CIN/FN-related chemotherapy disturbance","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","paramType":"Odds Ratio (OR)","paramValue":"0.999","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"1.000","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.001","groupDescription":"Chemotherapy-treated cancer patients in 2009 (per 1 patient) as center-level predictor for CIN/FN-related chemotherapy disturbance","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"1.001","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"1.127","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.353","groupDescription":"Center type: academic vs non-academic as center-level predictor for CIN/FN-related chemotherapy disturbance","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.024","paramType":"Odds Ratio (OR)","paramValue":"2.456","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"1.342","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.331","groupDescription":"Center type: academic-affiliated vs non-academic as center-level predictor for CIN/FN-related chemotherapy disturbance","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.010","paramType":"Odds Ratio (OR)","paramValue":"3.344","statisticalMethod":"Regression, Logistic","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1045"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"3376"}],"units":"cycles"}],"description":"Objective 8: To model patient- and center-level variables between patients who responded and those who did not respond to primary or secondary prophylaxis with EP2006.\n\nObjective 9: To model patient- and center-level variables between patients who had chemotherapy dose delays or reductions, surgery delays and cancellations, and radiotherapy delays, dose reductions, or cancellations vs. no such events during the course of primary or secondary prophylaxis with EP2006.\n\nOnly results with a p-value of \\<0.05 are shown in the statistical appendices.\n\nCI: confidence interval; CIN: chemotherapy-induced neutropenia; GCSF: granulocyte colony-stimulating factor; GIS: GCSF Initiation Score; Chemotherapy disturbance=dose reduction, delay, and/or cancellation","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Cycles of patients in evaluable sample with CIN/FN-related chemotherapy disturbance with data","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Modeling CIN/FN-related Chemotherapy Disturbance: Cycle Level","type":"SECONDARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}